PHXMP Stock Overview
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
PHAXIAM Therapeutics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.32 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 1.81 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -93.56% |
| 5 Year Change | -94.83% |
| Change since IPO | -95.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHXMP | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 3.7% | 2.3% |
| 1Y | n/a | -23.4% | 5.6% |
Return vs Industry: Insufficient data to determine how PHXMP performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how PHXMP performed against the UK Market.
Price Volatility
| PHXMP volatility | |
|---|---|
| PHXMP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: PHXMP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PHXMP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 45 | Thibaut Fayet | www.phaxiam.com |
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.
PHAXIAM Therapeutics S.A. Fundamentals Summary
| PHXMP fundamental statistics | |
|---|---|
| Market cap | €18.47m |
| Earnings (TTM) | -€11.96m |
| Revenue (TTM) | €5.70m |
3.2x
P/S Ratio-1.5x
P/E RatioIs PHXMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHXMP income statement (TTM) | |
|---|---|
| Revenue | €5.70m |
| Cost of Revenue | €0 |
| Gross Profit | €5.70m |
| Other Expenses | €17.66m |
| Earnings | -€11.96m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Mar 20, 2024
| Earnings per share (EPS) | -1.97 |
| Gross Margin | 100.00% |
| Net Profit Margin | -209.79% |
| Debt/Equity Ratio | 41.3% |
How did PHXMP perform over the long term?
See historical performance and comparison